CBWTF:OTC-Auxly Cannabis Group Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | OTC

Last Closing Price

USD 0.23

Change

-0.01 (-4.24)%

Market Cap

USD 0.15B

Volume

1.36M

Average Target Price

USD 0.40 (+76.99%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Auxly Cannabis Group Inc. operates as a consumer packaged goods company in the cannabis products market in Canada. The company engages in the cultivation of cannabis; and development and distribution of cannabis products. It offers products, such as soft chews, vape cartridges, vape pens, pre-rolled cannabis, chocolates, and cannabis oil spray and oil drops through retail stores under the Kolab Project, Foray, and Dosecan brand names. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. Auxly Cannabis Group Inc. was incorporated in 1987 and is based in Vancouver, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-01 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY MERCK Kommanditgesellschaft au..

+0.40 (+1.25%)

USD69.21B 30.88 16.40
MKGAF MERCK Kommanditgesellschaft au..

+0.54 (+0.34%)

USD68.89B 30.67 16.86
TKPHF Takeda Pharmaceutical Company ..

+0.01 (+0.03%)

USD56.08B 21.95 0.13
ESALF Eisai Co., Ltd

N/A

USD21.36B 35.58 0.12
ESALY Eisai Co., Ltd

+0.16 (+0.21%)

USD21.16B 36.05 0.12
SFOSF Shanghai Fosun Pharmaceutical ..

+0.13 (+3.03%)

USD17.93B 25.38 3.37
SGIOF Shionogi & Co., Ltd

-0.35 (-0.65%)

USD16.59B 16.33 0.08
SGIOY Shionogi & Co., Ltd

+0.13 (+0.98%)

USD16.51B 2.02 0.08
TEVJF Teva Pharmaceutical Industries..

N/A

USD11.16B 900.00 16.02
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21

ETFs Containing CBWTF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -47.07% 29% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.07% 29% F 13% F
Trailing 12 Months  
Capital Gain -52.42% 27% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -52.42% 27% F 11% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -26.96% N/A N/A 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.96% N/A N/A 6% F
Risk Return Profile  
Volatility (Standard Deviation) 27.19% N/A N/A 61% D-
Risk Adjusted Return -99.12% N/A N/A 4% F
Market Capitalization 0.15B 82% B- 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.84 68% D+ 68% D+
Price / Cash Flow Ratio -1.87 55% F 69% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -47.34% 50% F 18% F
Return on Invested Capital -13.40% 51% F 22% F
Return on Assets -9.90% 61% D- 32% F
Debt to Equity Ratio 34.39% 33% F 47% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 3.46 11% F 8% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector